CoChat

Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies

Open access
Watts, Eleanor L., Appleby, Paul N., Perez-Cornago, Aurora, Bueno-de-Mesquita, H. Bas, Chan, June M., Chen, Chu, Cohn, Barbara A., Cook, Michael B., Flicker, Leon, Freedman, Neal D., Giles, Graham G., Giovannucci, Edward, Gislefoss, Randi E., Hankey, Graeme J., Kaaks, Rudolf, Knekt, Paul, Kolonel, Laurence N., Kubo, Tatsuhiko, Le Marchand, Loïc, Luben, Robert N., Luostarinen, Tapio, Männistö, Satu, Metter, E. Jeffrey, Mikami, Kazuya, Milne, Roger L., Ozasa, Kotaro, Platz, Elizabeth A., Quirós, J. Ramón, Rissanen, Harri, Sawada, Norie, Stampfer, Meir, Stanczyk, Frank Z., Stattin, Pär, Tamakoshi, Akiko, Tangen, Catherine M., Thompson, Ian M., Tsilidis, Konstantinos K., Tsugane, Shoichiro, Ursin, Giske, Vatten, Lars, Weiss, Noel S., Yeap, Bu B., Allen, Naomi E., Key, Timothy J., Travis, Ruth C. · 2018 · European Urology
Cited by 115

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Experimental and clinical evidence implicates testosterone in the aetiology of prostate cancer. Variation across the normal range of circulating free testosterone concentrations may not lead to changes in prostate biology, unless circulating concentrations are low. This may also apply to prostate cancer risk, but this has not been investigated in an epidemiological setting. OBJECTIVE: To examine whether men with low concentrations of circulating free testosterone have a reduced risk of prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: Analysis of individual participant data from 20 prospective studies including 6933 prostate cancer cases, diagnosed on average 6.8 yr after blood collection, and 12 088 controls in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Odds ratios (ORs) of incident overall prostate cancer and subtypes by stage and grade, using conditional logistic regression, based on study-specific tenths of calculated free testosterone concentration. RESULTS AND LIMITATIONS: =0.01), with a lower risk of low-grade disease (OR=0.76, 95% CI 0.67-0.88) and a nonsignificantly higher risk of high-grade disease (OR=1.56, 95% CI 0.95-2.57). There was no evidence of heterogeneity by tumour stage. The observational design is a limitation. CONCLUSIONS: Men with low circulating free testosterone may have a lower risk of overall prostate cancer; this may be due to a direct biological effect, or detection bias. Further research is needed to explore the apparent differential association by tumour grade. PATIENT SUMMARY: In this study, we looked at circulating testosterone levels and risk of developing prostate cancer, finding that men with low testosterone had a lower risk of prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2018.07.024

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 36

  1. Taylor, 2010, Integrative genomic profiling of human prostate cancer, Cancer Cell, 18, 11, 10.1016/j.ccr.2010.05.026 · DOI · Paper page
  2. Thompson, 2013, Long-term survival of participants in the Prostate Cancer Prevention Trial, N Engl J Med, 369, 603, 10.1056/NEJMoa1215932 · DOI · Paper page
  3. Andriole, 2010, Effect of dutasteride on the risk of prostate cancer, N Engl J Med, 362, 1192, 10.1056/NEJMoa0908127 · DOI · Paper page
  4. Thompson, 2003, The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, 215, 10.1056/NEJMoa030660 · DOI · Paper page
  5. Bu, 2016, Putative prostate cancer risk SNP in an androgen receptor-binding site of the melanophilin gene illustrates enrichment of risk SNPs in androgen receptor target sites, Hum Mutat, 37, 52, 10.1002/humu.22909 · DOI
  6. Thomas, 2008, Multiple loci identified in a genome-wide association study of prostate cancer, Nat Genet, 40, 310, 10.1038/ng.91 · DOI · Paper page
  7. Pollard, 1982, Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone, Prostate, 3, 563, 10.1002/pros.2990030605 · doi:10.1002/pros.2990030605
  8. Bosland, 2014, Testosterone treatment is a potent tumor promoter for the rat prostate, Endocrinology, 155, 4629, 10.1210/en.2014-1688 · DOI
  9. Roddam, 2008, Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies, J Natl Cancer Inst, 100, 170, 10.1093/jnci/djm323 · DOI · Paper page
  10. Swerdloff, 2017, Dihydrotestosterone: biochemistry, physiology, and clinical Implications of elevated blood levels, Endocr Rev, 38, 220, 10.1210/er.2016-1067 · DOI · Paper page
  11. Morgentaler, 2009, Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth, Eur Urol, 55, 310, 10.1016/j.eururo.2008.09.024 · DOI · Paper page
  12. Weber, 1989, The influence of reversible androgen deprivation on serum prostate-specific antigen levels in men with benign prostatic hyperplasia, J Urol, 141, 987, 10.1016/S0022-5347(17)41083-4 · DOI
  13. Nickel, 2004, Comparison of clinical trials with finasteride and dutasteride, Rev Urol, 6, S31
  14. Goldman, 2017, A reappraisal of testosterone's binding in circulation: physiological and clinical implications, Endocr Rev, 38, 302, 10.1210/er.2017-00025 · DOI · Paper page
  15. Bartsch, 1980, Interrelationships between sex hormone-binding globulin and testosterone, 5 alpha-dihydrotestosterone and oestradiol-17 beta in blood of normal men, Maturitas, 2, 109, 10.1016/0378-5122(80)90044-4 · DOI
  16. Key, 2010, Pooling biomarker data from different studies of disease risk, with a focus on endogenous hormones, Cancer Epidemiol Biomarkers Prev, 19, 960, 10.1158/1055-9965.EPI-10-0061 · DOI
  17. Easton, 1991, Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group, Stat Med, 10, 1025, 10.1002/sim.4780100703 · DOI · Paper page
  18. Plummer, 2004, Improved estimates of floating absolute risk, Stat Med, 23, 93, 10.1002/sim.1485 · DOI · Paper page
  19. Muller, 2012, Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events Trial, Eur Urol, 62, 757, 10.1016/j.eururo.2012.05.025 · DOI
  20. Legler, 1998, The role of prostate-specific antigen (PSA) testing patterns in the recent prostate cancer incidence decline in the United States, Cancer Causes Control, 9, 519, 10.1023/A:1008805718310 · DOI
  21. Kim, 2004, Prostate specific antigen gene regulation by androgen receptor, J Cell Biochem, 93, 233, 10.1002/jcb.20228 · DOI · Paper page
  22. Platz, 2005, Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era, Cancer Epidemiol Biomarkers Prev, 14, 1262, 10.1158/1055-9965.EPI-04-0371 · DOI · Paper page
  23. Schatzl, 2001, High-grade prostate cancer is associated with low serum testosterone levels, Prostate, 47, 52, 10.1002/pros.1046 · DOI · Paper page
  24. Hoffman, 2000, Is low serum free testosterone a marker for high grade prostate cancer?, J Urol, 163, 824, 10.1016/S0022-5347(05)67812-3 · DOI · Paper page
  25. Bayar, 2017, Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial, Turk J Urol, 43, 289, 10.5152/tud.2017.35467 · DOI
  26. Penney, 2013, Gleason grade progression is uncommon, Cancer Res, 73, 5163, 10.1158/0008-5472.CAN-13-0427 · doi:10.1158/0008-5472.can-13-0427
  27. Wu, 2007, Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor, Proc Natl Acad Sci USA, 104, 12679, 10.1073/pnas.0704940104 · DOI · Paper page
  28. Cunha, 1987, The endocrinology and developmental biology of the prostate, Endocr Rev, 8, 338, 10.1210/edrv-8-3-338 · DOI · Paper page
  29. Briganti, 2007, Prostate volume and adverse prostate cancer features: fact not artifact, Eur J Cancer, 43, 2669, 10.1016/j.ejca.2007.09.022 · doi:10.1016/j.ejca.2007.09.022
  30. Cohen, 2007, Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 99, 1366, 10.1093/jnci/djm130 · DOI
  31. Lucia, 2007, Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial, J Natl Cancer Inst, 99, 1375, 10.1093/jnci/djm117 · DOI · Paper page
  32. Civantos, 1996, Histopathological effects of androgen deprivation in prostatic cancer, Semin Urol Oncol, 14, 22
  33. Reuter, 1997, Pathological changes in benign and malignant prostatic tissue following androgen deprivation therapy, Urology, 49, 16, 10.1016/S0090-4295(97)00164-7 · DOI
  34. Thompson, 2006, Effect of finasteride on the sensitivity of PSA for detecting prostate cancer, JNCI, 98, 1128, 10.1093/jnci/djj307 · DOI · Paper page
  35. Hsing, 2007, Reproducibility of serum sex steroid assays in men by RIA and mass spectrometry, Cancer Epidemiol Biomarkers Prev, 16, 1004, 10.1158/1055-9965.EPI-06-0792 · DOI · Paper page
  36. Vermeulen, 1992, Representativeness of a single point plasma testosterone level for the long term hormonal milieu in men, J Clin Endocrinol Metab, 74, 939, 10.1210/jcem.74.4.1548361 · doi:10.1210/jcem.74.4.1548361 · Paper page

Cited by

See all 115

Metadata

Authors
Watts, E. L., Appleby, P. N., Perez-Cornago, A., Bueno-de-Mesquita, H. B., Chan, J. M., Chen, C., Cohn, B. A., Cook, M. B., Flicker, L., Freedman, N. D., Giles, G. G., Giovannucci, E., Gislefoss, R. E., Hankey, G. J., Kaaks, R., Knekt, P., Kolonel, L. N., Kubo, T., Le Marchand, L., Luben, R. N., Luostarinen, T., Männistö, S., Metter, E. J., Mikami, K., Milne, R. L., Ozasa, K., Platz, E. A., Quirós, J. R., Rissanen, H., Sawada, N., Stampfer, M., Stanczyk, F. Z., Stattin, P., Tamakoshi, A., Tangen, C. M., Thompson, I. M., Tsilidis, K. K., Tsugane, S., Ursin, G., Vatten, L., Weiss, N. S., Yeap, B. B., Allen, N. E., Key, T. J., & Travis, R. C.
Venue
European Urology
Publisher
Elsevier BV
Published
2018-11
Volume
74
Issue
5
Pages
585-594
ISSN
0302-2838 (ISSN-L)
OpenAlex
W2886173583
Cited by
115
References
4
FWCI
7.27
Type
journal article
Language
en
Open access
hybrid
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. https://app.cochat.ai/papers/10.1016/j.eururo.2018.07.024
The paper
Watts, E. L., Appleby, P. N., Perez-Cornago, A., Bueno-de-Mesquita, H. B., Chan, J. M., Chen, C., Cohn, B. A., Cook, M. B., Flicker, L., Freedman, N. D., Giles, G. G., Giovannucci, E., Gislefoss, R. E., Hankey, G. J., Kaaks, R., Knekt, P., Kolonel, L. N., Kubo, T., Le Marchand, L., . . . Travis, R. C. (2018). Low Free Testosterone and Prostate Cancer Risk: A Collaborative Analysis of 20 Prospective Studies. European Urology. https://doi.org/10.1016/j.eururo.2018.07.024

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.